In general, observational studies that involve human subjects require Institutional Review Board (IRB) approval to ensure that the study is conducted in an ethical manner and that the rights and welfare of study participants are protected. This applies to both clinical trials and observational studies, including those using real-world evidence (RWE).
IRB approval is required because observational studies may involve the collection of personal or sensitive information from study participants, or the implementation of interventions or procedures that may pose risks to participants. IRBs review study protocols to ensure that the study design is scientifically sound, that the risks to participants are minimized, and that the potential benefits of the study outweigh any potential harms.
However, there are some exceptions to this requirement for IRB approval. For example, if the RWE study uses de-identified data and does not involve any interventions or interactions with human subjects, IRB approval may not be required. Additionally, certain types of RWE studies may be exempt from IRB review under certain circumstances, such as studies that use existing data and do not involve the collection of new data from human subjects.
It is important to note that the specific requirements for IRB approval may vary by country or region, and by the specific study design and research question. Therefore, it is important to consult with local regulations and guidelines, as well as with an IRB or ethics committee, to determine whether IRB approval is required for a specific observational study using RWE.
Share this story...
Real World Evidence (RWE) 101 – Patient Retention
RWE 101 - Patient Retention Long-term Real-World Evidence (RWE) studies face significant challenges when it comes to patient retention, for several reasons:[1] Time Commitment: Participants in RWE studies are [...]
Real World Evidence (RWE) 101 – Patient Recruitment
RWE 101 - Patient Recruitment Real-world evidence (RWE) is health care information derived from real-world data (RWD). It can be generated through various study designs or analyses, including pragmatic [...]
Real World Evidence (RWE) 101 – HARPER
RWE 101 - HARPER Regulatory agencies, health technology assessors, and payers are increasingly interested in studies that make use of real-world data to inform regulatory and other policy or [...]
Real World Evidence (RWE) 101 – STaRT-RWE
RWE 101 - STaRT-RWE START-RWE (Structured Template for Planning and Reporting on the Implementation of Real World Evidence Studies) was developed to address the need for improved transparency and [...]
Real World Evidence (RWE) 101 – Protocol Design and ISPE GPP
RWE 101 - Protocol Design and ISPE GPP The International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) are a set of best practices for the conduct [...]
Real World Evidence (RWE) 101 – Protocol Design and Scientific Best Practices
RWE 101 - Protocol Design and Scientific Best Practices Designing a robust Real-World Evidence (RWE) study is crucial for generating reliable and valid insights that are acceptable to regulators. [...]







